The AB partnership with Spiral Therapeutics aims to explore the integration of novel drug-delivery methods with future cochlear implant technology.
Advanced Bionics (AB), a developer of cochlear implant technology, has announced an equity investment and research collaboration with Spiral Therapeutics, a company specializing in therapies for inner ear disorders. The collaboration will explore how Spiral’s drug-delivery technologies could be integrated with AB’s cochlear implant development.
The partnership will focus on investigating how Spiral Therapeutics’ drug-delivery platform could be utilized during cochlear implant surgery. Spiral’s platform is designed for minimally invasive, precise, and durable delivery of therapeutics to the cochlea. The companies will explore potential solutions for unmet needs in the cochlear implant field.
“Through this collaboration, we are combining two highly complementary R&D capabilities to explore what could become a new innovation chapter in cochlear implant technology,” says Fernando Chapa, senior vice president, global R&D Advanced Bionics, in a release. “Our focus is firmly on responsible, science-driven development that has the potential to benefit patients in meaningful ways over time.”
This early-stage R&D effort aligns with Advanced Bionics’ stated mission of investing in technologies to improve outcomes for individuals with hearing loss. Advanced Bionics is a subsidiary of the Sonova Group.
